Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells
NCT01587690 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24
Last updated 2013-11-20
Summary
MicroRNAs regulate gene expression. The abnormal expression of microRNAs has been reported in many human diseases. The purpose of this pilot study is to determine if microRNA expression is changed in untreated and interferon-beta-treated patients with multiple sclerosis.
Conditions
Sponsors & Collaborators
-
Rutgers, The State University of New Jersey
lead OTHER
Principal Investigators
-
Konstantin Balashov, MD, PhD · Rutgers-RWJMS
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-11-30
- Primary Completion
- 2013-01-31
- Completion
- 2013-01-31
Countries
- United States
Study Locations
More Related Trials
-
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 ·Status: TERMINATED ·Phase: PHASE2
-
The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis
NCT06290453 ·Status: NOT_YET_RECRUITING
-
MicroRNA-150 and microRNA-155 in Multiple Sclerosis
NCT04300543 ·Status: UNKNOWN
-
Measuring Active Microglia in Progressive Multiple Sclerosis
NCT02207075 ·Status: COMPLETED
-
Immunodeficiency in MS
NCT04447937 ·Status: UNKNOWN
-
Gene Expression in MS Patients Before and During Treatment With Interferon-beta
NCT00202384 ·Status: TERMINATED
-
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
NCT05849467 ·Status: RECRUITING ·Phase: PHASE1
-
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
NCT01737372 ·Status: COMPLETED
-
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
NCT02845635 ·Status: COMPLETED
-
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
NCT00468182 ·Status: COMPLETED
-
Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM)
NCT05828901 ·Status: TERMINATED
-
Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
NCT02769767 ·Status: UNKNOWN
-
Gene Expression Profiles in Multiple Sclerosis (MS)
NCT00704834 ·Status: COMPLETED
-
Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study
NCT03369106 ·Status: ACTIVE_NOT_RECRUITING
-
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
NCT02364986 ·Status: UNKNOWN ·Phase: PHASE1
-
Assessment of Patients With Multiple Sclerosis (MS)
NCT00001156 ·Status: COMPLETED
-
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00917839 ·Status: UNKNOWN ·Phase: PHASE2
-
Understanding Magnetic Resonance Imaging in Multiple Sclerosis
NCT03872583 ·Status: COMPLETED ·Phase: NA
-
Advanced MRI Sequences in Multiple Sclerosis and Its Mimics
NCT03608605 ·Status: UNKNOWN
-
Immunisation Status and Safety of Vaccines in Italian MS Patients
NCT04300868 ·Status: UNKNOWN
-
Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic
NCT05056740 ·Status: RECRUITING
-
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
NCT00079495 ·Status: COMPLETED ·Phase: PHASE2
-
Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis
NCT05061953 ·Status: RECRUITING
-
Genes and Environment in Multiple Sclerosis
NCT01353547 ·Status: RECRUITING
-
Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis
NCT00645749 ·Status: COMPLETED ·Phase: PHASE1